

Disorder-to-order conformational transitions in protein structure and its relationship to disease

Paola Mendoza-Espinosa · Victor García-González ·
Abel Moreno · Rolando Castillo · Jaime Mas-Oliva

Received: 4 December 2008 / Accepted: 30 March 2009 / Published online: 9 April 2009
© Springer Science+Business Media, LLC. 2009

Abstract Function in proteins largely depends on the acquisition of specific structures through folding at physiological time scales. Under both equilibrium and non-equilibrium states, proteins develop partially structured molecules that being intermediates in the process, usually resemble the structure of the fully folded protein. These intermediates, known as molten globules, present the faculty of adopting a large variety of conformations mainly supported by changes in their side chains. Taking into account that the mechanism to obtain a fully packed structure is considered more difficult energetically than forming partially “disordered” folding intermediates, evolution might have conferred upon an important number of proteins the capability to first partially fold and—depending on the presence of specific partner ligands—switch on disorder-to-order transitions to adopt a highly ordered well-folded state and reach the lowest energy conformation possible. Disorder in this context can represent segments of proteins or complete proteins that might exist in the native state. Moreover, because this type of disorder-to-order transition in proteins has been found to be reversible, it has been frequently associated with important signaling events in the cell. Due to the central role of this

phenomenon in cell biology, protein misfolding and aberrant disorder-to-order transitions have been at present associated with an important number of diseases.

Keywords Protein structure · Protein misfolding · Disorder-to-order transitions · Disease

Introduction

Although for many years now human disease has been directly related with specific anomalies in protein–protein, protein–DNA and protein–RNA interactions, in the near future such accumulated knowledge will require expansion in order to take the next technological step with the application of many proteomic concepts to patient-oriented therapies [1]. Recently in this regard, an important number of diseases have been associated with problems specifically related with protein folding. The concept of protein folding is directly related with the process of reversible disorder-to-order transitions, by which an unfolded polypeptide chain folds into a specific functional native structure [2, 3]. Although for a long time it was thought to be only a theoretical concept, it was only recently that it became clear that incorrectly folded proteins might be related with the development of disease. From that time, conformational or protein-folding diseases have been divided basically into two groups. The first, includes errors in the genetic blueprint that leads to incomplete or incorrectly folded proteins directly affecting function; classical examples of this group comprise malfunction of p53 as a critical tumor suppressor protein directly related with cancer [4, 5] and specific alterations in diseases such as cystic fibrosis [6] and sickle cell anemia [7]. The second group, which is made up to excessive quantities of incorrectly conformed proteins

P. Mendoza-Espinosa · V. García-González · J. Mas-Oliva (✉)
Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Apdo. Postal 70-243, 04510 Mexico, D.F., Mexico
e-mail: jmas@ifc.unam.mx

A. Moreno
Instituto de Química, Universidad Nacional Autónoma de México, Mexico, D.F., Mexico

R. Castillo
Instituto de Física, Universidad Nacional Autónoma de México, Mexico, D.F., Mexico

causes the formation of multimolecular structures or plaques with the property of altering normal cell function. Such alterations, known as amyloidosis, are found in diseases like Alzheimer disease [8], Creutzfeldt–Jakob disease [9], Parkinson disease [10], and type II non-insulin-dependent diabetes mellitus [11]. Although in all of the previously mentioned diseases, protein aggregates or plaques are known to be constituted of amyloid fibrils polymerized as beta-sheet structures, important factors involved in the process dealing first with formation and propagation, and second with their stability are far from being understood *in vivo*.

Physicochemical approach

For folding into a native state, unfolded polypeptide chains require the intervention of weak interactions. Driven by hydrophobic interactions, a polypeptide chain begins to fold when placed in an aqueous medium, and rapidly becomes a molten globule followed by an important release of latent heat. Stabilization of the molten globule is achieved mainly through the distribution of hydrophobic residues away from the water matrix. On the other hand, because the polar residues contained in a protein develop hydrogen bonds with the water network as well as with each other, α -helices and β -sheets can be formed when bonds switch between molecules. It has been calculated that such bonds might be in the order of 10^{-12} s, very similar to those we find in water itself. The random equilibrium can be shifted toward one of these conformations by means of two stages: a fast stage, during which the unfolded polypeptide becomes a molten globule; and a slow stage, in which the molten globule slowly transforms into a fully folded form or native state [12]. These two stages in protein folding can be illustrated by a “folding funnel”, during which due to a small change in entropy with a large loss of energy, a molten globule evolves into the native state (Fig. 1) [13, 14]. Although the process is extremely efficient, there is always the possibility that this accurate mechanism might fail, and the possibility of finding a protein folded into a non-native state becomes a reality [15]. Proteins that follow this pathway might present transiently stable conformations, promoting their interaction with other molecules and facilitating the fact that they might form amorphous oligomers and end in a state of aggregation. Aggregation does not arise from a random coil state, but rather from a series of intermediates that—based on the type of secondary structure acquired during folding—might or might not resemble the native state (Fig. 2) [14, 16]. It is well known now that primary polypeptide sequences become the key factor during this process, while the environment surrounding the protein is an important





Fig. 1 Folding funnel energy landscape. Globular proteins organize themselves from a random coil to a molten globule during a large loss of entropy and small changes in energy. However, the molten globule becomes transformed to a native state during a low change in entropy at the expense of a large loss of energy. Adapted from references [12–14]

factor for explaining the folding process [17]. On the other hand, natively unfolded proteins, known to lack the presence of permanent secondary and tertiary structures, have been recognized at least in the absence of other proteins, to present the tendency to organize themselves into amyloidogenic structures. This is the case for α -synuclein, an important protein found in Lewy bodies in the brain of patients affected with Parkinson disease [18]. In the case of prion diseases, the P_rP protein has been isolated from amyloid plaques, in which a clear conformational change in secondary structure from α -helix into β -sheet following a templating mechanism has been recognized as the process that causes aggregation [17].

Considering that the native state is located at the lowest minimum of the “folding funnel”, it indicates that this region is the most thermodynamically stable configuration of the polypeptide chain under physiological conditions. For proteins, whose functional state is a tightly packed globular fold, a key step in fibril formation related to partial or complete unfolding is less likely to occur and therefore remains protected against aggregation [19]. In this respect, it has been proposed that the more transient structures thus formed in proteins, the better probability for key determinants in amyloid fibril formation to be found [20]. Thus, many of the known forms of amyloid diseases are

Fig. 2 Protein aggregation energy landscape. Although the funnel shape for protein folding is organized from an active process that results in the selection of forms with favorable native contacts, when a high concentration of polypeptide is present, a large number of interactions appear followed by protein aggregation. Landscape regions characterized by low energy and low entropy are recognized for the appearance of well-ordered species such as fibrils and crystals. Adapted from reference [14]



associated with genetic mutations that decrease protein stability and promote unfolding [20], both related to disorder-to-order conformational transitions.

Chen et al. showed that monomeric polyglutamine in solution represents the nucleus for aggregation and nucleation of a β -sheet aggregate through an initial disorder-to-order transition [21]. Multiple molecular dynamic simulations have provided quantitative characterization of these polyglutamine peptides showing disorder-to-order fluctuations directly related to chain length and average compactness [22]. Here, it was shown that the concentration of side chain primary amides around backbone units and solvation, either by hydrogen bonds or surrounding water molecules, importantly contribute to these average compactness values [22]. In this context, the first experimental evidence about a specific disorder-to-order transition was presented over 30 years ago with the mechanism description for the conversion of trypsinogen to trypsin [23]. This mechanism is characterized by the enzymatic removal of a hexapeptide from the N-terminal region of trypsinogen in order to form trypsin. This basic change promotes the transition from a disordered state of the “specificity pocket” in trypsinogen to an ordered state in trypsin [24].

Since it is known that several amino acids that make up a protein strongly favor a disordered state, at present this “new view” of folding is beginning to be further studied, in which the influence of external or environmental

conditions sustains well-tested transitions between disordered and ordered states [25–27]. Specific polypeptide chains contained in proteins or complete proteins lacking defined tertiary structures are known to have the capacity to undergo disorder-to-order transitions upon binding to specific [28] or multiple partners [29]. It is precisely this ability that allows the concept of “protein disorder” to be proposed as an important feature in the capability of proteins to present regions with switching properties [30–32]. Dunker and Obradovic [26] and later Uversky [27] designed a protein/function paradigm extended from the classic form of thought in which ordered 3D structures are indispensable for function due to the fact that the function might arise from ordered structures as efficiently as from disordered functions, namely pre-molten globules and random coils (Fig. 3). An example of the latter would be α -synuclein, shown to be partially folded in the presence of di- and trivalent metal ions, in which in response to cation-binding intrinsic coils change into a pre-molten globular conformation [33]. On the other hand, structural arrangements that take place from a random coil to a molten globule-like conformation have been observed with the myelin basic protein upon binding to lipids [34]. From an evolutionary point of view, it appears that intrinsic disorder in proteins might have been the driving force behind many of the adaptability processes found in proteins [15, 35].




Fig. 3 Protein quartet model for protein structure transitions. Adapted from references [26, 27]

Taking into account that the number of proteins presenting disordered regions directly related with function and therefore with disease is increasingly growing, an interest to also generate accessible data banks for improving information management has increased. Therefore, the database of disordered proteins (DisProt) was created and released in August 2006 by the group of Dunker [36] with extremely good results at present [37]. Since then, other systems for studying disorder in proteins have been released, such as the Integrated Protein Disorder Analyzer, which aims at identifying and predicting disordered region in proteins [38], or algorithms for predicting and evaluating aggregation “hot spots” (AGGRESKAN) [39]. According to Dunker’s group and as predicted by PONDR^r [40], a large percentage of all proteins involved with some sort of a disease have been identified as directly related with disordered regions in proteins closely associated with signaling.

Protein conformational diseases

From a general point of view, disordered regions in proteins have been divided into the following two classes: the class in which proteins retain a low percentage of secondary structure together with unstable tertiary structures during a molten globule state, recognized as the collapsed class; and second, the class in which proteins with a highly extended backbone resemble a β -sheet conformation related with the extended class [25, 41]. In general, proteins containing disordered regions have been recognized as associated with several human diseases, including cardiovascular disease, cancer, degenerative diseases, and diabetes. Interestingly, because in many of these cases cell signaling function has been involved, there is a strong possibility that disorder-to-order transitions in proteins playing normal switching roles in the cell might become distorted and therefore abolish or transform the normal protein–protein language into an aberrant one. Therefore, the basic properties of a switching

mechanism must be based on the equilibrium between high specificity and weak affinities accompanied by a large conformational entropy decrease. This phenomenon is based principally on the fact that upon binding, disorder-to-order transitions can overcome steric restrictions and thereby enable larger interaction surfaces in protein–protein complexes than those that could be obtained for rigid partners [42]. Despite the extraordinary importance of this type of transition, we continue to lack detailed biophysical studies that might demonstrate a close relationship between this type of disorder-to-order organization and protein function.

During the last few years and mainly employing powerful bioinformatics and data mining, many proteins showing intrinsic disorder have been studied in relationship with the disease [43, 44]. A good number of these proteins can be considered as potential candidates in the understanding and treatment of the disease when specific group domains undergoing abnormal disorder-to-order transitions are recognized [42, 45]. An example of this possibility is the lymphoid enhancer-binding factor 1 (LEF-1), which corresponds to a sequence-specific and cell type-specific transcription factor playing a key role in T-cell receptor (TCR)- α gene-enhancer modulation [46]. Based on circular dichroism studies, helix I adopts a helical structure and becomes fully stabilized, reaching a well-folded state in the presence of DNA [47].

Another example corresponds to the p53 tumor-suppressor protein as one of the most studied proteins in history. It is known that p53 activates a large number of genes, with its main function being the arrest of the cell cycle in G1 and G2, allowing the activation of DNA repair mechanisms and therefore the development of its cancer-inhibiting properties. Persons inheriting only one functional copy of the p53 gene are predisposed to develop several tumor types. This condition has been found in the Li-Fraumeni syndrome (LFS), in which individuals are predisposed to develop sarcomas, leukemias, adrenocortical carcinomas, and breast cancer at early ages [48, 49]. More than 50% of human cancers have been associated with mutations in p53, and according to systematic analysis of a large number of mutations, it has been revealed that 304 of the 882 mutations studied affecting the structure of the p53 core domain can be explained by their effects on protein folding [50]. Although reversible aggregation appears to play an important role in p53 core-domain folding [51], it remains to be studied whether a percentage of the structural changes found with this important protein might be associated with localized disorder-to-order transitions, which in turn could modulate—and therefore affect, for example—protein–DNA interactions.

Moreover, with regard to RNA function, several RNA chaperones with key participation in cellular RNA metabolism have been described as organizing several networks of RNA–RNA, RNA–protein, and protein–protein interactions




Fig. 4 Structural conformations for the NCp7 (Zn-finger) protein. **a** Relatively unstructured NCp7 (residues 12–53) showing coordination with zinc atoms in purple around a poorly structured section. **b** In the presence of DNA (HIV-1 primer binding site) a change in secondary structure (α -helix, *blue*) is observed, when a complex is

formed around the HIV-primer binding site of DNA and the N-terminal region of NCp7 (Zn-finger). Structures were obtained from PDB access code: 1esk and 2jzw. Images visualized employing the Pymol program [212]

[52]. Here, these chaperone proteins presenting an important intrinsic disorder assist RNA function by successive disorder-to-order and order-to-disorder transition cycles to aid RNA in acquiring the most stable conformation required for optimal function [53]. One classical example is NCp7, a nucleocapsid protein from the HIV type 1 virus. NCp7 is a 55 amino-acid nucleic-acid-binding protein that represents an important structural segment of the HIV type 1 virus nucleocapsid. It is characterized by two zinc fingers [54, 55] and participates in several key functions during the HIV-1 viral life cycle [56–58]. The two main activities of NCp7 are destabilization of nucleic acid loop structures [59–61] and nucleic acid aggregation–condensation [62–64]. NCp7 has been mainly studied through its interaction with four contiguous stem-loop structures, where SL1–SL4 of the HIV-1 ψ recognition site [65–67] shows a high degree of disorder [53] and therefore excellent adaptation properties for a wide range of RNA and DNA molecules (Fig. 4) [66–70].

Lipid transfer protein structure and disease

In an attempt to define the possibility that folding key features in proteins could provide us with the manner in which to explain basic issues such as receptor recognition, lipid transfer activity, and self-exchangeability carried out by several lipid transfer proteins including apolipoproteins, our group has attempted to address these points by directly measuring molecular conformational changes of apolipoproteins at air/water and lipid/water interfaces, in order to approach the possible mechanisms that might explain these phenomena [71]. This has been achieved employing Langmuir monolayers in conjunction with Brewster angle microscopy (BAM), atomic force microscopy (AFM) of LB films of protein [72–75], grazing incidence X-ray

diffraction on protein monolayers [76], and surface force measurements (SFA) [77]. Because at that time, we were unable to define whether the secondary structure of specific segments of apoCI and -AII remained stable independently of their position at air/water and lipid/water interfaces, more recently we have addressed the possibility that these segments responding to specific environmental changes and following disorder-to-order transitions might function as molecular switches that trigger function [78, 79].

ApoCI is synthesized with a 26-residue signal peptide that is cleaved co-translationally in the rough endoplasmic reticulum which inhibits both phospholipase A2 [80, 81] and hepatic lipase [82] and activates the lecithin-cholesterol acyltransferase (LCAT) [83]. Also, it has been reported that the C-terminal fragment of human apoCI acts as an inhibitor in vitro of the cholesterol ester transfer protein (CETP) [84, 85]. On the other hand, the discovery that apoE-enriched β -migrating very-low-density lipoprotein (β -VLDL) binds to the lipoprotein receptor-related protein (LRP) [86], the effect of apoCI content upon this binding has been studied [87]. When individual members of the C apolipoprotein family were examined, it was found that apoCI is the most potent inhibitor of apoE-mediated β -VLDL binding to the lipoprotein-related protein (LRP) [88]. It has been suggested that in addition to displacement of apoE from the particle, apoCI binding might exert its effect by inducing a change in resident apoE conformation, which in turn abolishes its ability to interact with LRP. Apolipoprotein E is a 299-residue protein that exists as three allelic variants, denominated apo E2, -3, and -4. In Alzheimer disease, the apo E4 allele is a risk factor associated with an earlier age of onset for sporadic cases [89, 90].

Although function that depends specifically on 100% disordered proteins represents the extreme case, the concept of having disordered segments in proteins that only respond and acquire a well-defined secondary structure associated with the binding of specific ligands, might be more common than we thought. We have postulated that changes in lipid composition of HDL particles might promote an alteration in normal disorder-to-order transitions found in apoCI, changing its switching properties, and therefore predisposing the onset of diseases related with LCAT activation and CETP function [79]. Acquisition of a very rapid lipid-specific α -helical conformation following a disorder-to-order transition in the C-terminal peptide of apoCI has provided new insights into how this protein might modulate function [77, 79]. Moreover, following the same approach with specific peptides synthesized from the reported structure of apolipoprotein A1, when left in water at 4°C, a very slow disorder-to-order transition develops over the course of weeks, from a fully disordered state to a well-developed β -sheet secondary structure (Mas-Oliva J, personal communication). This behavior further supports the fact that the physicochemical characteristics of the environment must be considered as a key factor in the equilibrium displacement within the secondary structure of a protein or specific segments toward α -helices or β -sheets [91]. Here, the result that specific segments of apolipoprotein AI slowly develop fibril-like structures indicates the possibility that pathological processes such as atherogenesis might be also considered as an amyloidotic-related process (Fig. 5) [92].

Amyloid-related diseases

At present, an important number of human diseases affecting several tissues and producing a series of common




Fig. 5 Atomic force microscopy image of apolipoprotein AI-peptide DRV (amino acids 9–24) (Mas-Oliva J, personal communication). Fibrils show an average length of 300 nm and 25 nm in height

symptoms find their origin in the assembly of proteins into insoluble deposits [93, 94]. Although absolute establishment of this connection is lacking to date, there is solid evidence indicating a strong correlation between the formation of amyloid fibrils and their toxicity upon cells in vitro [95–97]. The missing point continues to reside in basic understanding of the characteristics of the so-called amyloidogenic proteins that define their capacity to organize themselves into a β -structure conformation. This capacity has been, on the one hand, related to a hereditary component with several dominant autosomic diseases [98], and on the other, with a “sporadic” form of the disease [98, 99]. Here, independently of whether the precursor protein is being synthesized as a normal protein, secondary external factors mainly related with the protein environment during synthesis or during transit to its target pathway, define their potential amyloidotic pathway. Because not every protein that aggregates forms amyloid deposits, the study—and eventually the understanding—of the mechanisms that govern, first, protein folding and second, aggregation-related phenomena, include possible implications for disorder-to-order transitions. Again, the potential implications of having disordered segments in these proteins that might present conformational transitions to ordered states still remains to be fully evaluated.

Amyloid-related diseases are in direct association to a failure of the regulatory mechanisms that normally ensure that proteins remain in their correctly folded functional states [13]. Such mechanisms and quality control systems include the action of folding catalysts, molecular chaperones, degrading enzymes, and endoplasmic reticulum-associated degradation, that normally detect misfolded or damaged proteins and either rescue or destroy them [19, 100]. If the function of these protective mechanisms is diminished, the probability of pathogenesis increases [101, 102].

On the other hand, several studies have shown that a certain number of polypeptides not directly related to amyloid disease might be also capable of forming amyloid fibrils under destabilized conditions [103–108]. This shows that amyloid deposition may be a common property of proteins, and not only to the ones associated with disease [109]. In fact, the difference between “functional” amyloids and the ones associated to disease might be explained in terms of evolutionary regulating mechanisms. These mechanisms might have evolved functional amyloids where cellular toxicity associated to their formation might have been quenched by other proteins [110] as in the case of protein Pmel17 [111, 112]. Pmel17 corresponds to a transmembrane protein located in the plasma membrane of melanocytes [113]. This protein is of central importance in the way melanin is polymerized in melanocytes since Mx, a proteolytic fragment of Pmel17 structured as amyloid fibrils

functions as a key support in the polymerization of melanin [111]. Since it has been shown that amyloidogenesis of $M\alpha$ is four orders of magnitude faster than $A\beta$ and α -synuclein, we can consider this optimized process of fibrillogenesis as an evolutionary way to avoid intrinsic toxicity mostly associated to fibril polymerization [112].

Amyloids are basically classified according to the process-specific protein rather than their clinical manifestations. One of the most important models for studying amyloidogenesis has been the one that occurs during inflammation [114, 115]. This model has been useful in the study of the common characteristics among amyloids, in which an acute phase related with protein synthesis in liver has been described. Because many amyloid peptides/proteins correspond to a fragment of larger precursor molecules, it has been observed that usually a 1,000-fold increase in the plasma concentration of these precursors is needed in order to start the deposition of amyloid. Proteolytic processing of these precursors associated with an altered expression of a series of sorting and trafficking factors appears to be a pathogenic factor in the formation of amyloid deposits [116].

To date, many proteins have been proposed as presenting amyloidogenic properties. Interestingly, on examining their shared characteristics from the perspective of primary structure, no common features are found among them. Therefore, their amyloidogenic properties must rely on the secondary and tertiary levels. Kinetic data are consistent with the possibility that “intermediate” or “molten globule-like” conformational states are in equilibrium, and that the process of fibril formation takes place only by shifting this equilibrium [117]. Since amyloidogenesis corresponds to a two-step reaction with a slow lag period related with the formation of a nucleation center and as a secondary stage its propagation, this process has been compared with protein crystallization [118]. The presence of metal ions and the association with accessory proteins such as apolipoproteins and sulfated proteoglycans has shown the property to modulate amyloidogenesis [119–121]. Therefore, the sometimes denominated *pathological chaperones* have also been shown to contribute to amyloid toxicity [122].

Amyloid-associated proteoglycans

Perhaps the most common amyloid-associated molecules are proteoglycans, which contain a large number of sulfate glycosaminoglycan (GAG) chains linked to large molecular-weight protein cores [123, 124]. The possibility that GAG interaction contributes as a driving force in fibril assembly and amyloid plaque formation has been suggested [125]. In this context, sulfated proteoglycans are ubiquitously expressed on various cell membranes and they are common to all type of amyloids studied to date. They have been also suggested as key factors in the formation of

mature plaques serving as scaffolds and protecting against proteolysis [126–128]. Several subtypes have been associated with $A\beta$ plaques, including heparin, dermatan, keratin, and chondroitin sulfate proteoglycans [129, 130].

It seems that the most common amyloid-associated proteoglycan is perlecan [130, 131] that constitutes the major component of the basement membrane/extracellular matrix proteoglycan of the cell [127, 132, 133]. Perlecan has been associated to virtually all human amyloid diseases including Alzheimer’s disease, familial amyloidosis, and type 2 diabetes [128, 134–137]. Although several in vitro studies have shown that sulfated GAG chains can induce extensive $A\beta$ aggregation via electrostatic interactions [138] and have been found to increase the β -sheet content of several amyloidogenic proteins such as serum amyloid A protein (SAA) [139], sulfated GAG chains also seem to reduce amyloid fibril degradation [140]. The SAA [139] has been reported to contain specific binding sites for heparin and heparan sulfate, associated to phylogenetically conserved basic residues. The occupation of these sites is likely to increase the amyloid conformation of SAA [141].

β amyloid precursor protein ($A\beta$ PP) and β amyloid ($A\beta$)

Together with its precursor protein, the amyloid peptide is considered a normal molecule found in plasma, cerebrospinal fluid, and the extracellular space. $A\beta$ PP corresponds to a transmembrane protein with a low amyloidogenesis potential in vitro. This is in contrast with the high tendency of $A\beta$ to form fibril aggregates [142]. Three $A\beta$ PP isoforms are shown to date (751, 770, and 695 amino-acids) [143] and all of them, followed by the action of an α -secretase, form a soluble ectodomain with the retention in the membrane of the carboxy end fragment [144]. Secondary to the action of β and γ secretases, $A\beta$ is liberated generating diverse forms of the β amyloid peptides ranging in size from 39 to 43 residues, being $A\beta_{42}$, the one with the highest fibrillogenic potential (Fig. 6) [145]. Several years ago, we found that upon activation platelets secrete a 120 kDa proteoglycan that presents the ability to inhibit acetylated-low-density-lipoprotein internalization through binding to the scavenger receptor class A (SR-A) in macrophages [124]. This proteoglycan was identified as an α -secretase product of $A\beta$ PP [146]. This finding supports the possibility that SR-A might participate in the clearance of several forms of $A\beta$ PP from atherosclerotic lesions, thus contributing to the reduction of foam cell formation. Moreover, competition of $A\beta$ PP for β -amyloid uptake by microglial cells through the SR-A, might contribute to β -amyloid accumulation in the brain’s extracellular space. Although changes in secondary structure of $A\beta$ PP related to a disorder-to-order transition has not been addressed, at




Fig. 6 Structural representation of $A\beta$ peptides. **a** Primary sequence of $A\beta$ fragment 17–42 showing segments that correspond to $\beta 1$ (18–26) and $\beta 2$ (31–42) connected through a poorly structured region (residues 27–30). **b** Fibrillar structure of $A\beta$ (17–42) obtained with NMR and mutagenesis complementation methodologies. The structure shows a pentamer with interchain distances of approximately 4.7 Å. **c** Lateral view through the axis of an $A\beta$ fiber showing the lateral amino-acid residues of both β -sheets separated by a 10 Å gap. PDB access code: 2beg. Images visualized employing the Pymol program [212]

this stage this possibility can not be discarded. β -amyloid has been also shown to promote an important cellular oxidative state [147] and further promote, for example, the development of Alzheimer disease, the most common amyloidosis and leading cause of dementia among the elderly.

The amyloid-enhancing factor (AEF) is defined as a factor that dramatically shortens the induction time for amyloid development during inflammatory processes (from 36 h to 2–3 weeks). This characteristic is consistent with amyloidogenesis requiring a nucleating event that shortens initiation of the process. Likewise, many AEF characteristics are related with experiments in which exogenously delivered prions have been injected, and apparently served as templates for endogenously synthesized prions transformed into pathologically active agents [148, 149]. However, different from prions, AEF generates amyloidosis only in the presence of an inflammatory event, reason why instead of being an infective agent it is considered a potentiator of the disease [150].

Prion disease

Prion diseases are chronic neurodegenerative disorders associated with the accumulation of abnormal isoforms of

PrP protein in the brain. Among these diseases, we recognize at present scrapie (in sheep and goat), spongiform encephalopathy (in cattle) [151, 152], and in the human, Kuru [153], Creutzfeldt–Jakob disease (CJD) [154], fatal familial insomnia (FFI), Gerstmann–Sträusler–Scheiker disease (GSS), and PrP-cerebral amyloid angiopathy (PrP-CAA) [155–157]. The cellular prion protein (PrP^c) corresponds to a single gene-encoded 35 kDa sialoglycoprotein [158]. The translated protein contains 253 amino acids with glycine/proline-rich octopeptide repeats spanning residues 51–91. It is polymorphic at residue 129 with methionine/valine and at residue 219 with glutamic acid/lysine, and is glycosylated at residues 181 and 197 [159]. Circular dichroism has shown that PrP^c presents a high content of α -helical secondary structure and shows no β -sheet conformation [160]. It is transported in secretory vesicles while anchored to these structures through a GPI moiety [161]. Although the normal function for PrP^c remains unknown, it has been suggested that it might play a role in synaptic function [162]. Because PrP knockout mice have shown to be resistant to development of scrapie, it has been postulated that synthesis of the normal form of PrP^c is an absolute pre-requisite in this protein's abnormal form (PrP^{sc}), which involves a conformational change from an




Fig. 7 Structure of the prion like domain of HET-s (218–289). **a** Primary sequence of HET-s fragment 218–289 showing segments that correspond to β -strands $\beta 1a$ (226–229), $\beta 1b$ (230–234), $\beta 2a$ (236–241), $\beta 2b$ (243–246) and $\beta 3a$ (262–265), $\beta 3b$ (266–270), $\beta 4a$ (272–277) and $\beta 4b$ (279–282) separated by a poorly structured region (residues 247–261). **b** Side view of five domains of HET-s (218–289) calculated from solid state NMR with a tridimensional structure in the form of a left-handed- β -solenoid. Each color represents a single domain. **c** Side view of a single domain showing β -structured regions as marked in (a). PDB access code: 2nmn. Images visualized employing the Pymol program [212]

α -helix-based structure into β -sheets [163]. Prion rods possess the same tinctorial properties of amyloid fibers (binding the amyloidophilic fluorophores thioflavin and Congo red) [164] and resemble amyloid fibrils found in vivo (Fig. 7) [165, 166].

Peripheral nerve amyloidosis and transthyretin (TTR)

Peripheral nerve amyloidosis is common in familial amyloid polyneuropathy (FAP) [167] and can be a key feature in primary light chain amyloidosis and β 2-microglobulin-related amyloidosis. FAPs are a heterogeneous group of autosomal dominant disorders characterized by deposition of a fibrillar protein associated to transthyretin (TTR) in the form of amyloid [168, 169]. TTR composed of four identical 127 residue subunits is the plasma protein responsible for transport of thyroxin and vitamin A [170, 171]. Although several mutations in TTR causing extracellular tissue-selective deposition have been described [172], the clinical basis for the predominant manifestation of each mutation has not been established yet [173]. Nevertheless, pathogenesis has been associated with dissociation of the native tetramer molecule into partially unfolded species, which can subsequently self-assemble in the form of amyloid fibrils (Fig. 8) [174–177].




Fig. 8 Three-dimensional structure of the transthyretin monomer obtained from X-ray diffraction. Arrows represent β -sheet secondary structure showing in color the position of regions with the most common amyloidogenic mutations. White color represents regions with no incidence of mutation, red one mutation, green two-three mutations, and blue four or more mutations. Citation for each mutation can be found at the TTR database of mutations maintained by C. E. Costello at Boston University School of Medicine (<http://www.bumc.bu.edu/msr/trr-database/>). PDB access code: 1rlb. Image visualized employing the Pymol program [212]

FAP can also occur secondary to apolipoprotein A-I [178] and gelsolin deposition [179], where two mutations described in the gelsolin gene have been directly associated to this type of disease [180, 181]. In this respect, it has been also shown that serum apo A-II concentrations are much higher in patients with FAP than in normal controls or asymptomatic carriers, suggesting that apo A-II may play a role in amyloid formation in these patients [182]. Moreover, the disease known as familial amyloidosis of Finnish type (FAF) related to gelsolin deposition is characterized by progressive cranial neuropathy, corneal dystrophy, and skin elasticity complications [183, 184]. The first step in FAF is determined by an aberrant proteolysis carried out by furin [185] followed by the proteolytic cut of a MT1-matrix metalloprotease generating amyloidogenic peptides of 5 or 8 kDa [186].

Islet amyloid polypeptide (IAPP) and Beta 2 microglobulin (β 2m)

IAPP or amylin synthesized in pancreatic islet β -cells suffers a series of post-translational modifications to yield a mature 37-amino acid peptide (Fig. 9) [187, 188]. IAPP is a molecule involved in the modulation of glucose metabolism [189, 190] as well as in calcium metabolism [191]. IAPP aggregates are the primary component of amyloid deposits found in the pancreatic β -cells of patients with type 2 diabetes mellitus [192]. Prefibrillar oligomeric IAPP has been shown the property to permeabilize membranes through a pore-like mechanism, suggesting that this process might be related to the pathogenic mechanism involved in the genesis of non-insulin-dependent (type II) diabetes mellitus (NIDDM) and other amyloid-related diseases [193]. In adult diabetes (type II), it has been




Fig. 9 Three-dimensional structure of human amylin. **a** Primary amino-acid sequence of the entire amylin molecule (1–37) showing in red the amyloidogenic region in between S20 and S29. A mutation that changes S20 for G20 has been directly related to the most severe cases of non insulin dependent diabetes mellitus (NIDDM). **b** Secondary structure of amylin determined by NMR using SDS micelles. The amyloidogenic region of amylin is shown in red as in (a). PDB access code: 2kb8. Image visualized employing the Pymol program [212]

observed that 90% or more of patients with this disorder present amyloid deposits in the islets of Langerhans [194].

$\beta 2m$ is a protein found in a noncovalently association with the heavy chain of major histocompatibility class I complex (MHCI). Due to the natural turnover of $\beta 2m$, it is normally found in plasma and therefore carried to the kidneys where it is degraded and excreted [195]. Due to renal dysfunction, the concentration of $\beta 2m$ in plasma can increase up to 60-fold, where it accumulates as a filamentous structure in connective tissues and leads to dialysis-related amyloidosis [196–198]. Although it is known that dissociation from MHCI predisposes the amyloid-transition of $\beta 2m$ [199], the mechanism underlying $\beta 2m$ fibrillogenesis in vivo is still largely unknown [200, 201].

Concluding remarks

According to scientists working in different fields of knowledge, nature appears to have employed disorder to create high levels of organization. Moreover, in some cases nature seems to have created disorder, when there is, in the first place a lack of it [202]. This latter situation extrapolated to medicine has shown that many diseases find their origin in the way proteins carry out many structural changes employing finely tuned disorder-to-order and order-to-disorder transitions.

Taking into account that several amyloid-functional-structures have been characterized in bacteria [203, 204], fungi [205–207], insects [208, 209], and mammals [111, 210], there is consensus that the formation of amyloid fibrils represents a well conserved evolutive pathway in protein structure [110, 211]. Therefore, differences between “functional” and “pathological” amyloids might simply reside in the modulatory pathways involved along their synthesis. As professor Christopher M. Dobson has stated, “One can therefore think of the amyloid diseases as resulting from the reversion of the highly evolved biologically functional forms of peptides and proteins into an alternative and unwelcome structural state that exists as a result of the inherent physicochemical nature of polypeptide chains” [19]. Without a doubt we can state that in the near future, many diseases with still unknown origins will find their explanation in the way this class of phenomenon is regulated.

Acknowledgments Research described in this article carried out during the last few years in the laboratory of JM-O has been supported by Consejo Nacional de Ciencia y Tecnología, México (CONACyT-México) grant 47333/A-1 and by Universidad Nacional Autónoma de México (DGAPA-UNAM) grant IN228607. We want to thank Blanca Delgado-Coello for her technical help and Jorge Bravo-Martínez for his work in visualization and structure analysis, Mrs.

Margaret Brunner for editorial services and Ma. Elena Gutierrez for manuscript preparation.

References

- Beretta L (2007) Proteomics from the clinical perspective: many hopes and much debate. *Nat Methods* 4:785–786. doi:10.1038/nmeth1007-785
- Rose GD, Fleming PJ, Banavar JR, Maritan A (2006) A backbone-based theory of protein folding. *Proc Natl Acad Sci USA* 103:16623–16633. doi:10.1073/pnas.0606843103
- Eaton WA, Muñoz V, Hagen SJ, Jas GS, Lapidus LJ, Henry ER (2000) Fast kinetics and mechanisms in protein folding. *Annu Rev Biophys Biomol Struct* 29:327–359. doi:10.1146/annurev.biophys.29.1.327
- Levine AJ (1997) p53, the cellular gatekeeper for growth and division. *Cell* 88:323–331. doi:10.1016/S0092-8674(00)81871-1
- Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. *Nature* 408:307–310. doi:10.1038/35042675
- Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. *Proc Natl Acad Sci USA* 102:10427–10432. doi:10.1073/pnas.0502066102
- Frenette PS, Atweh GF (2007) Sickle cell disease: old discoveries, new concepts, and future promise. *J Clin Invest* 117:850–858. doi:10.1172/JCI30920
- Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer’s beta-amyloid fibrils. *Science* 307:262–265. doi:10.1126/science.1105850
- Yull HM, Ritchie DL, Langeveld JP, van Zijderveld FG, Bruce ME, Ironside JW, Head MW (2006) Detection of type 1 prion protein in variant Creutzfeldt–Jakob disease. *Am J Pathol* 168:151–157. doi:10.2353/ajpath.2006.050766
- Selkoe DJ (2003) Folding proteins in fatal ways. *Nature* 426:900–904. doi:10.1038/nature02264
- Hoening M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O’Brien T (2000) A feline model of experimentally induced islet amyloidosis. *Am J Pathol* 157:2143–2150
- Huang K (2005) Lectures on statistical physics and protein folding. World Scientific, New Jersey
- Dobson CM (2003) Protein folding and misfolding. *Nature* 426:884–890. doi:10.1038/nature02261
- Gsponer J, Vendruscolo M (2006) Theoretical approaches to protein aggregation. *Protein Pept Lett* 13:287–293. doi:10.2174/092986606775338407
- Dobson CM (1999) Protein misfolding, evolution and disease. *Trends Biochem Sci* 24:329–332. doi:10.1016/S0968-0004(99)01445-0
- Eisenberg D, Nelson R, Sawaya MR, Balbirnie M, Sambashivan S, Ivanova MI, Madsen AO, Riek C (2006) The structural biology of protein aggregation diseases: fundamental questions and some answers. *Acc Chem Res* 39:568–575. doi:10.1021/ar0500618
- Fink AL (1998) Protein aggregation: folding aggregates, inclusion bodies and amyloid. *Fold Des* 3:R9–R23. doi:10.1016/S1359-0278(98)00002-9
- Chandra S, Chen X, Rizo J, Jahn R, Südhof TC (2003) A broken alpha-helix in folded alpha-synuclein. *J Biol Chem* 278:15313–15318. doi:10.1074/jbc.M213128200
- Dobson MC (2004) Protein chemistry: in the footsteps of alchemists. *Science* 304:1259–1262. doi:10.1126/science.1093078
- Ohnishi S, Takano K (2004) Amyloid fibrils from the viewpoint of protein folding. *Cell Mol Life Sci* 61:511–524. doi:10.1007/s00018-003-3264-8

21. Chen S, Ferrone FA, Wetzel R (2002) Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. *Proc Natl Acad Sci USA* 99:11884–11889. doi:10.1073/pnas.182276099
22. Wang X, Vitalis A, Wyczalkowski MA, Pappu RV (2006) Characterizing the conformational ensemble of monomeric polyglutamine. *Proteins* 63:297–311. doi:10.1002/prot.20761
23. Bode W, Huber R (1976) Induction of the bovine trypsinogen-trypsin transition by peptides sequentially similar to the N-terminus of trypsin. *FEBS Lett* 68:231–236. doi:10.1016/0014-5793(76)80443-7
24. Huber R, Bode W (1978) Structural basis of the activation and action of trypsin. *Acc Chem Res* 11:114–122. doi:10.1021/ar50123a006
25. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW, Ausio J, Nissen MS, Reeves R, Kang C, Kissinger CR, Bailey RW, Griswold MD, Chiu W, Garner EC, Obradovic ZJ (2001) Intrinsically disordered protein. *J Mol Graph Model* 19:26–59. doi:10.1016/S1093-3263(00)00138-8
26. Dunker AK, Obradovic Z (2001) The protein trinity-linking function and disorder. *Nat Biotechnol* 19:805–806. doi:10.1038/nbt0901-805
27. Uversky VN (2002) Natively unfolded proteins: a point where biology waits for physics. *Protein Sci* 11:739–756. doi:10.1110/ps.4210102
28. Tompa P (2002) Intrinsically unstructured proteins. *Trends Biochem Sci* 27:527–533. doi:10.1016/S0968-0004(02)02169-2
29. James C, Tawfik DS (2003) Conformational diversity and protein evolution—a 60-year-old hypothesis revisited. *Trends Biochem Sci* 28:361–368. doi:10.1016/S0968-0004(03)00135-X
30. Bustos DM, Iglesias AA (2006) Intrinsic disorder is a key characteristic in partners that bind 14-3-3 proteins. *Proteins* 63:35–42. doi:10.1002/prot.20888
31. Kriwacki RW, Hengst L, Tennant L, Reed SI, Wright PE (1996) Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. *Proc Natl Acad Sci USA* 93:11504–11509. doi:10.1073/pnas.93.21.11504
32. Dalal S, Regan L (2000) Understanding the sequence determinants of conformational switching using protein design. *Protein Sci* 9:1651–1659. doi:10.1110/ps.9.9.1651
33. Pagel K, Vagt T, Koksche B (2005) Directing the secondary structure of polypeptides at will: from helices to amyloids and back again? *Org Biomol Chem* 3:3843–3850. doi:10.1039/b510098d
34. Polverini E, Fasano A, Zito F, Riccio P, Cavatorta P (1999) Conformation of bovine myelin basic protein purified with bound lipids. *Eur Biophys J* 28:351–355. doi:10.1007/s002490050218
35. Dunker AK, Garner E, Guillot S, Romero P, Albrecht K, Hart J, Obradovic Z, Kissinger C, Villafranca JE (1998) Protein disorder and the evolution of molecular recognition: theory, predictions and observations. *Pac Symp Biocomput* 473–484
36. Sickmeier M, Hamilton JA, LeGall T, Vacic V, Cortese MS, Tatos A, Szabo B, Tompa P, Chen J, Uversky VN, Obradovic Z, Dunker AK (2007) DisProt: the database of disordered proteins. *Nucleic Acids Res* 35:D786–D793. doi:10.1093/nar/gkl893
37. Cortese MS, Uversky VN, Dunker AK (2008) Intrinsic disorder in scaffold proteins: getting more from less. *Prog Biophys Mol Biol* 98:85–106. doi:10.1016/j.pbiomolbio.2008.05.007
38. Su C-T, Chen C-Y, Hsu C-M (2007) iPDA: integrated protein disorder analyzer. *Nucleic Acids Res* 35:W465–W472. doi:10.1093/nar/gkm080
39. Conchillo-Solé O, de Groot NS, Avilés FX, Vendrell J, Daura X, Ventura S (2007) AGGRESCAN: a server for the prediction and evaluation of “hot spots” of aggregation in polypeptides. *BMC Bioinformatics* 8:65. doi:10.1186/1471-2105-8-65
40. Romero PZ, Obradovic C, Dunker AK (2001) Intelligent data analysis for protein disorder prediction. *Artif Intell Rev* 14:447–484. doi:10.1023/A:1006678623815
41. Uversky VN (2002) What does it mean to be natively unfolded? *Eur J Biochem* 269:2–12. doi:10.1046/j.0014-2956.2001.02649.x
42. Cheng Y, LeGall T, Oldfield CJ, Mueller JP, Van YY, Romero P, Cortese MS, Uversky VN, Dunker AK (2006) Rational drug design via intrinsically disordered protein. *Trends Biotechnol* 24:435–442. doi:10.1016/j.tibtech.2006.07.005
43. Xie Q, Arnold GE, Romero P, Obradovic Z, Garner E, Dunker AK (1998) The sequence attribute method for determining relationships between sequence and protein disorder. *Genome Inform Ser Workshop Genome Inform* 9:193–200
44. Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK (2001) Sequence complexity of disordered protein. *Proteins* 42:38–48. doi:10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
45. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z (2002) Intrinsic disorder and protein function. *Biochemistry* 41:6573–6582. doi:10.1021/bi012159+
46. Held W, Clevers H, Grosschedl R (2003) Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. *Eur J Immunol* 33:1393–1398. doi:10.1002/eji.200323840
47. Love JJ, Li X, Chung J, Dyson HJ, Wright PE (2004) The LEF-1 high-mobility group domain undergoes a disorder-to-order transition upon formation of a complex with cognate DNA. *Biochemistry* 43:8725–8734. doi:10.1021/bi049591m
48. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Edem PB, Evans DGR, Thompson E, Mann JR, Martin J, Mithel ELD, Santibáñez-Koref F (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. *Cancer Res* 54:1298–1304
49. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 63:6643–6650
50. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton JM (2002) Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. *Hum Mutat* 19:149–164. doi:10.1002/humu.10032
51. Ishimaru D, Lima LMTR, Naia LF, Lopez PM, Bom APA, Valente AP, Silva JL (2004) Reversible aggregation plays a crucial role on the folding landscape of p53 core domain. *Biophys J* 87:2691–2700. doi:10.1529/biophysj.104.044685
52. Ivanyi-Nagy R, Davidovic L, Khandjian EW, Darlix JL (2005) Disordered RNA chaperone proteins: from functions to disease. *Cell Mol Life Sci* 62:1409–1417. doi:10.1007/s00018-005-5100-9
53. Tompa P, Csermely P (2004) The role of structural disorder in the function of RNA and protein chaperones. *FASEB J* 18:1169–1175. doi:10.1096/fj.04-1584rev
54. Mély Y, De Rocquigny H, Morellet N, Roques BP, Gerad D (1996) Zinc binding to the HIV-1 nucleocapsid protein: a thermodynamic investigation by fluorescence spectroscopy. *Biochemistry* 35:5175–5182. doi:10.1021/bi952587d
55. South TL, Blake PR, Sowder CK 3rd, Arthur LO, Henderson LE, Summers MF (1990) The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers. *Biochemistry* 29:7786–7789. doi:10.1021/bi00486a002
56. Carteau S, Gorelick RJ, Bushman FD (1999) Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. *J Virol* 73:6670–6679

57. Cristofari G, Darlix JL (2002) The ubiquitous nature of RNA chaperone proteins. *Prog Nucleic Acid Res Mol Biol* 72:223–268. doi:10.1016/S0079-6603(02)72071-0
58. Tsuchihashi Z, Brown PO (1994) DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. *J Virol* 68:5863–5870
59. Hargittai MR, Gorelick RJ, Rouzina I, Musier-Forsyth K (2004) Mechanistic insights into the kinetics of HIV-1 nucleocapsid protein-facilitated tRNA annealing to the primer binding site. *J Mol Biol* 337:951–968. doi:10.1016/j.jmb.2004.01.054
60. Urbaneja MA, Wu M, Casas-Finet JR, Karpel RL (2002) HIV-1 nucleocapsid protein as a nucleic acid chaperone: spectroscopic study of its helix-destabilizing properties, structural binding specificity, and annealing activity. *J Mol Biol* 318:749–764. doi:10.1016/S0022-2836(02)00043-8
61. Williams MC, Rouzina I, Wenner JR, Gorelick RJ, Musier-Forsyth K, Bloomfield VA (2001) Mechanism for nucleic acid chaperone activity of HIV-1 nucleocapsid protein revealed by single molecule stretching. *Proc Natl Acad Sci USA* 98:6121–6126. doi:10.1073/pnas.101033198
62. Dib-Hajj F, Khan R, Giedroc DP (1993) Retroviral nucleocapsid proteins possess potent nucleic acid strand renaturation activity. *Protein Sci* 2:231–243
63. Kankia BI, Barany G, Musier-Forsyth K (2005) Unfolding of DNA quadruplexes induced by HIV-1 nucleocapsid protein. *Nucleic Acids Res* 33:4395–4403. doi:10.1093/nar/gki741
64. Stoylov SP, Vuilleumier C, Stoylova E, De Rocquigny H, Roques BP, Gérard D, Mély Y (1997) Ordered aggregation of ribonucleic acids by the human immunodeficiency virus type 1 nucleocapsid protein. *Biopolymers* 41:301–312. doi:10.1002/(SICI)1097-0282(199703)41:3<301::AID-BIP5>3.0.CO;2-W
65. De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, Summers MF (1998) Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. *Science* 279:384–388. doi:10.1126/science.279.5349.384
66. Amarasinghe GK, De Guzman RN, Turner RB, Chancellor KJ, Wu ZR, Summers MF (2000) NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA packaging signal. Implications for genome recognition. *J Mol Biol* 301:491–511. doi:10.1006/jmbi.2000.3979
67. Amarasinghe GK, Zhou J, Miskimon M, Chancellor KJ, McDonald JA, Matthews AG, Miller RR, Rouse MD, Summers MF (2001) Stem-loop SL4 of the HIV-1 psi RNA packaging signal exhibits weak affinity for the nucleocapsid protein. Structural studies and implications for genome recognition. *J Mol Biol* 314:961–970. doi:10.1006/jmbi.2000.5182
68. Tisné C, Roques BP, Dardel F (2001) Heteronuclear NMR studies of the interaction of tRNA(Lys)₃ with HIV-1 nucleocapsid protein. *J Mol Biol* 306:443–454. doi:10.1006/jmbi.2000.4391
69. Johnson PE, Turner RB, Wu ZR, Hairston L, Guo J, Levin JG, Summers MF (2000) A mechanism for plus-strand transfer enhancement by the HIV-1 nucleocapsid protein during reverse transcription. *Biochemistry* 39:9084–9091. doi:10.1021/bi000841i
70. Bourbigot S, Ramalanjaona N, Boudier C, Salgado GF, Roques BP, Mély Y, Bouaziz S, Morellet N (2008) How the HIV-1 nucleocapsid protein binds and destabilises the (–)primer binding site during reverse transcription. *J Mol Biol* 383:1112–1128. doi:10.1016/j.jmb.2008.08.046
71. Xicohtencatl-Cortes J, Castillo R, Mas-Oliva J (2004) In search of new structural states of exchangeable apolipoproteins. *Biochem Biophys Res Commun* 324:467–470. doi:10.1016/j.bbrc.2004.09.045
72. Bolaños-García VM, Mas-Oliva J, Ramos S, Castillo R (1999) Phase transitions in monolayers of human apolipoprotein C-I. *J Phys Chem B* 103:6236–6242. doi:10.1021/jp984342r
73. Bolaños-García VM, Ramos S, Xicohtencatl-Cortés J, Castillo R, Mas-Oliva J (2001) Monolayers of apolipoproteins at the air/water interface. *J Phys Chem B* 105:5757–5765. doi:10.1021/jp010714b
74. Mas-Oliva J, Moreno A, Ramos S, Xicohtencatl-Cortés J, Campos J, Castillo R (2003) Frontiers in cardiovascular health. In: Dhalla NS et al (eds) *Monolayers of apolipoprotein AII at the air/water interface*. Kluwer, Dordrecht, pp 341–352
75. Xicohtencatl-Cortes J, Mas-Oliva J, Castillo R (2004) Phase transitions of phospholipid monolayers penetrated by apolipoproteins. *J Phys Chem B* 108:7307–7315. doi:10.1021/jp0369443
76. Ruíz-García J, Moreno A, Brezesinski G, Möhwald H, Mas-Oliva J, Castillo R (2003) Phase transitions, conformational changes in monolayers of human apolipoprotein CI and AII. *J Phys Chem B* 107:11117–11124. doi:10.1021/jp034801a
77. Campos-Terán J, Mas-Oliva J, Castillo R (2004) Interactions and conformations of α -helical human apolipoprotein CI on hydrophilic and on hydrophobic substrates. *J Phys Chem B* 108:20442–20450. doi:10.1021/jp048305d
78. Ramos S, Campos-Terán J, Mas-Oliva J, Nylander T, Castillo R (2008) Forces between hydrophilic surfaces adsorbed with apolipoprotein AII alpha helices. *Langmuir* 24:8568–8575. doi:10.1021/la800348y
79. Mendoza-Espinosa P, Moreno A, Castillo R, Mas-Oliva J (2008) Lipid dependant disorder-to-order conformational transitions in apolipoprotein CI derived peptides. *Biochem Biophys Res Commun* 365:8–15. doi:10.1016/j.bbrc.2007.10.112
80. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS (2002) Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. *J Lipid Res* 43:2136–2145. doi:10.1194/jlr.M200210-JLR200
81. Poengen J (1990) Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes. *Biochim Biophys Acta* 1042:188–192
82. Kinnunen PK, Ehnholm C (1976) Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. *FEBS Lett* 65:354–357. doi:10.1016/0014-5793(76)80145-7
83. Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM, Smith LC (1975) Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. *Biochemistry* 14:3057–3064. doi:10.1021/bi00685a003
84. Gautier T, Masson D, de Barros JP, Athias A, Gambert P, Aunis D, Metz-Boutique MH, Lagrost L (2000) Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. *J Biol Chem* 275:37504–37509. doi:10.1074/jbc.M007210200
85. Dumont L, Gautier T, de Barros JP, Laplanche H, Blache D, Ducoroy P, Fruchart J, Fruchart JC, Gambert P, Masson D, Lagrost L (2005) Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. *J Biol Chem* 28:38108–38116. doi:10.1074/jbc.M504678200
86. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS (1989) Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. *Proc Natl Acad Sci USA* 86:5810–5814. doi:10.1073/pnas.86.15.5810
87. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL (1990) Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. *J Biol Chem* 265:10771–10779
88. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS (1990) Apolipoprotein C-I modulates the interaction

- of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. *J Biol Chem* 265: 22453–22459
89. Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. *Annu Rev Med* 47:387–400. doi:10.1146/annurev.med.47.1.387
 90. Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. *Am J Pathol* 157: 2093–2099
 91. Andreola A, Bellotti V, Giorgetti S, Mangione P, Obici L, Stoppini M, Torres J, Monzani E, Merlini G, Sunde M (2003) Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. *J Biol Chem* 278:2444–2451. doi:10.1074/jbc.M204801200
 92. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K (1995) Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. *Am J Pathol* 147:1186–1192
 93. Ban T, Hoshino M, Takahashi S, Hamada D, Hasegawa K, Naike H, Goto Y (2004) Direct observation of Abeta amyloid fibril growth and inhibition. *J Mol Biol* 344:757–767. doi:10.1016/j.jmb.2004.09.078
 94. Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. *Annu Rev Neurosci* 24:519–550. doi:10.1146/annurev.neuro.24.1.519
 95. Manzano-León N, Mas-Oliva J (2006) Estrés Oxidativo, Péptido β -amiloide y Enfermedad de Alzheimer. *Gac Med Mex* 142: 229–238
 96. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PL, Siedlak SL, Perry G (2007) Vascular oxidative stress in Alzheimer disease. *J Neurol Sci* 257:240–246. doi:10.1016/j.jns.2007.01.039
 97. Lazar KL, Miller-Auer H, Getz GS, Orgel JP, Meredith SC (2005) Helix-turn-helix peptides that form alpha-helical fibrils: turn sequences drive fibril structure. *Biochemistry* 44:12681–12689. doi:10.1021/bi0509705
 98. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM (2006) The cerebral beta-amyloid angiopathies: hereditary and sporadic. *Brain Pathol* 16:30–39. doi:10.1111/j.1750-3639.2006.tb00559.x
 99. Cabrejo L, Chassagne P, Doucet J, Laquerrière A, Puech N, Hannequin D (2006) Sporadic cerebral amyloidotic angiopathy. *Rev Neurol (Paris)* 162:1059–1067. doi:10.1016/S0035-3787(06)75118-9
 100. Bukau B, Weissman J, Horwich A (2006) Molecular chaperones and protein quality control. *Cell* 125:443–451. doi:10.1016/j.cell.2006.04.014
 101. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. *Science* 292:1552–1555. doi:10.1126/science.292.5521.1552
 102. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. *Neuron* 29:15–32. doi:10.1016/S0896-6273(01)00177-5
 103. Gross M, Wilkins DK, Pitkeathly MC, Chung EW, Higham C, Clark A, Dobson CM (1999) Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB. *Protein Sci* 8:1350–1357. doi:10.1110/ps.8.6.1350
 104. Krebs MR, Wilkins DK, Chung EW, Pitkeathly MC, Chamberlain AK, Zurdo J, Robinson CV, Dobson CM (2000) Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the beta-domain. *J Mol Biol* 300:541–549. doi:10.1006/jmbi.2000.3862
 105. Pertinhez TA, Bouchard M, Tomlinson EJ, Wain R, Ferguson SJ, Dobson CM, Smith LJ (2001) Amyloid fibril formation by a helical cytochrome. *FEBS Lett* 495:184–186. doi:10.1016/S0014-5793(01)02384-5
 106. Zurdo J, Guijarro JI, Jiménez JL, Saibil HR, Dobson CM (2001) Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. *J Mol Biol* 311:325–340. doi:10.1006/jmbi.2001.4858
 107. Srisailam S, Kumar TK, Rajalingam D, Kathir KM, Sheu HS, Jan FJ, Chao PC, Yu C (2003) Amyloid-like fibril formation in an all beta-barrel protein. Partially structured intermediate state(s) is a precursor for fibril formation. *J Biol Chem* 278:17701–17709. doi:10.1074/jbc.M300336200
 108. Fändrich M, Forge V, Buder K, Kittler M, Dobson CM, Diekmann S (2003) Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments. *Proc Natl Acad Sci USA* 100:15463–15468. doi:10.1073/pnas.0303758100
 109. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM (1998) Amyloid fibril formation by an SH3 domain. *Proc Natl Acad Sci USA* 95:4224–4228. doi:10.1073/pnas.95.8.4224
 110. Fowler DM, Koulov AV, Balch WE, Kelly JW (2007) Functional amyloid from bacteria to humans. *Trends Biochem Sci* 32:217–224. doi:10.1016/j.tibs.2007.03.003
 111. Berson JF, Theos AC, Harper DC, Tenza D, Raposo G, Marks MS (2003) Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. *J Cell Biol* 161:521–533. doi:10.1083/jcb.200302072
 112. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW (2006) Functional amyloid formation within mammalian tissue. *PLoS Biol* 4:e6
 113. Lee ZH, Hou L, Moellmann G, Kuklinska E, Antol K, Fraser M, Halaban R, Kwon BS (1996) Characterization and subcellular localization of human Pmel 17/silver, a 110-kDa (pre)melanosomal membrane protein associated with 5,6-dihydroxyindole-2-carboxylic acid (DHICA) converting activity. *J Invest Dermatol* 106:605–610. doi:10.1111/1523-1747.ep12345163
 114. Perry VH, Cunningham C, Boche D (2002) Atypical inflammation in the central nervous system in prion disease. *Curr Opin Neurol* 15:349–354. doi:10.1097/00019052-200206000-00020
 115. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Sahara T (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci* 27:10957–10968. doi:10.1523/JNEUROSCI.0673-07.2007
 116. von Arnim CA, Spoelgen R, Peltan ID, Deng M, Courchesne S, Koker M, Matsui T, Kowa H, Lichtenthaler SF, Irizarry MC, Hyman BT (2006) GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. *J Neurosci* 26:9913–9922. doi:10.1523/JNEUROSCI.2290-06.2006
 117. Morozova-Roche LA (2007) Equine lysozyme: the molecular basis of folding, self-assembly and innate amyloid toxicity. *FEBS Lett* 581:2587–2592. doi:10.1016/j.febslet.2007.05.023
 118. Wetzel R (2006) Kinetics and thermodynamics of amyloid fibril assembly. *Acc Chem Res* 39:671–679. doi:10.1021/ar050069h
 119. Magaki S, Raghavan R, Mueller C, Oberg KC, Vinters HV, Kirsch WM (2007) Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias. *Neurosci Lett* 418: 72–76. doi:10.1016/j.neulet.2007.02.077
 120. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE (2000) Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. *Mol Med* 6:430–439

121. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. *Biochem J* 316:671–679
122. Alexandrescu AT (2005) Amyloid accomplices and enforcers. *Protein Sci* 14:1–12. doi:10.1110/ps.04887005
123. Lindahl B, Eriksson L, Lindhal U (1995) Structure of heparan sulfate from human brain, with special regard to Alzheimer's disease. *Biochem J* 306:177–184
124. Mas-Oliva J, Arnold KS, Wagner WD, Phillips DR, Pitas RE, Innerarity TL (1994) Isolation and characterization of a platelet-derived macrophage-binding proteoglycan. *J Biol Chem* 269:10177–10183
125. Bussini S, Meda L, Scarpini E, Clementi E, Conti G, Tiriticco M, Bresolin N, Baron P (2005) Heparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia. *Immun Ageing* 2:11. doi:10.1186/1742-4933-2-11
126. Snow AD, Wight TN (1989) Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. *Neurobiol Aging* 10:481–497. doi:10.1016/0197-4580(89)90108-5
127. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD (1997) Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. *J Neurochem* 69:2452–2465
128. Ancsin JB (2003) Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. *Amyloid* 10:67–79
129. Arrasate M, Pérez M, Valpuesta JM, Avila J (1997) Role of glycosaminoglycans in determining the helicity of paired helical filaments. *Am J Pathol* 151:1115–1122
130. Brückner G, Hausen D, Härtig W, Drlicek M, Arendt T, Brauer K (1999) Cortical areas abundant in extracellular matrix chondroitin sulfate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. *Neuroscience* 92:791–805. doi:10.1016/S0306-4522(99)00071-8
131. Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K (1994) Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. *Am J Pathol* 144:337–347
132. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Scherier WA, Morgan DG (1994) An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. *Neuron* 12:219–234. doi:10.1016/0896-6273(94)90165-1
133. Kvangsakul M, Hopf M, Ries A, Timpl R, Hohenester E (2001) Structural basis for the high-affinity interaction of nidogen-1 with immunoglobulin-like domain 3 of perlecan. *EMBO J* 20:5342–5346. doi:10.1093/emboj/20.19.5342
134. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, Bruce Verchere C, Kahn SE, Wight TN (2003) Proteoglycans synthesized and secreted by pancreatic islet beta-cells bind amylin. *Arch Biochem Biophys* 413:182–190. doi:10.1016/S0003-9861(03)00116-4
135. Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. *Diabetes* 47:612–620. doi:10.2337/diabetes.47.4.612
136. Yamamoto S, Yamaguchi I, Hasegawa K, Tsutsumi S, Goto Y, Gejyo F, Naiki H (2004) Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. *J Am Soc Nephrol* 15:126–133. doi:10.1097/01.ASN.0000103228.81623.C7
137. Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW (2006) Heparin accelerates gelsolin amyloidogenesis. *Biochemistry* 45:2234–2242. doi:10.1021/bi0519295
138. Fraser PE, Nguyen JT, Chin DT, Kirschner DA (1992) Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril–proteoglycan interactions. *J Neurochem* 59:1531–1540. doi:10.1111/j.1471-4159.1992.tb08470.x
139. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R (1988) Circular-dichroism studies on two murine serum amyloid A proteins. *Biochem J* 256:775–783
140. Gupta-Bansal R, Frederickson RC, Brunden KR (1995) Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. *J Biol Chem* 270:18666–18671. doi:10.1074/jbc.270.31.18666
141. Ancsin JB, Kisilevsky R (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. *J Biol Chem* 274:7172–7181. doi:10.1074/jbc.274.11.7172
142. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The C-terminus of the beta protein is critical in amyloidogenesis. *Ann N Y Acad Sci* 695:144–148. doi:10.1111/j.1749-6632.1993.tb23043.x
143. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. *Annu Rev Cell Biol* 10:373–403. doi:10.1146/annurev.cb.10.110194.002105
144. Sisodia SS (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. *Proc Natl Acad Sci USA* 89:6075–6079. doi:10.1073/pnas.89.13.6075
145. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. *Science* 256:184–185. doi:10.1126/science.1566067
146. Santiago-García J, Mas-Oliva J, Innerarity TL, Pitas RE (2001) Secreted forms of the amyloid- β -precursor protein are ligands for the A scavenger receptor. *J Biol Chem* 276:30655–30661. doi:10.1074/jbc.M102879200
147. Manzano-León N, Delgado-Coello NB, Guaderrama-Díaz M, Mas-Oliva J (2006) Beta-adaptin: key molecule for microglial scavenger receptor function under oxidative stress. *Biochem Biophys Res Commun* 351:588–594. doi:10.1016/j.bbrc.2006.10.077
148. Varga J, Flinn MS, Shirahama T, Rodgers OG, Cohen AS (1986) The induction of accelerated murine amyloid with human splenic extract. Probable role of amyloid enhancing factor. *Virchows Arch B Cell Pathol Incl Mol Pathol* 51:177–185. doi:10.1007/BF02899027
149. Ganowiak K, Hultman P, Engström U, Gustavsson A, Westermarck P (1994) Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. *Biochem Biophys Res Commun* 199:306–312. doi:10.1006/bbrc.1994.1229
150. Soto C, Estrada L, Castilla J (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. *Trends Biochem Sci* 31:150–155. doi:10.1016/j.tibs.2006.01.002
151. Prusiner SB (1997) Prion diseases and the BSE crisis. *Science* 278:245–251. doi:10.1126/science.278.5336.245
152. Cohen FE, Prusiner SB (1998) Pathologic conformations of prion proteins. *Annu Rev Biochem* 67:793–819. doi:10.1146/annurev.biochem.67.1.793
153. Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, Prelli F, Farlow MR, Dlouhy SR, Tagliavini F (1996) Prion protein amyloidosis. *Brain Pathol* 6:127–145. doi:10.1111/j.1750-3639.1996.tb00796.x
154. Richardson EP, Masters CL (1995) The nosology of Creutzfeldt–Jakob disease and conditions related to the accumulation

- of PrPCJD in the nervous system. *Brain Pathol* 5:33–41. doi:10.1111/j.1750-3639.1995.tb00575.x
155. DeArmond SJ, Prusiner SB (1995) Prion protein transgenes and the neuropathology in prion diseases. *Brain Pathol* 5:77–89. doi:10.1111/j.1750-3639.1995.tb00579.x
 156. Giaccone G, Verga L, Bugiani O, Frangione B, Serban D, Prusiner SB, Farlow MR, Ghetti B, Tagliavini F (1992) Prion protein preamyloid and amyloid deposits in Gerstmann–Sträussler–Scheinker disease, Indiana kindred. *Proc Natl Acad Sci USA* 89:9349–9353. doi:10.1073/pnas.89.19.9349
 157. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. *J Neuropathol Exp Neurol* 62:885–898
 158. Liao YC, Lebo RV, Clawson GA, Smuckler EA (1986) Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications. *Science* 233:364–367. doi:10.1126/science.3014653
 159. Prusiner SB (1991) Molecular biology of prion diseases. *Science* 252:1515–1522. doi:10.1126/science.1675487
 160. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc Natl Acad Sci USA* 90:10962–10966. doi:10.1073/pnas.90.23.10962
 161. Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, Cohen F, Fletterick R, Prusiner SB (1992) Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. *Proc Natl Acad Sci USA* 89:10940–10944. doi:10.1073/pnas.89.22.10940
 162. Büeler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner SB (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 356:577–582. doi:10.1038/356577a0
 163. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (1993) Mice devoid of PrP are resistant to scrapie. *Cell* 73:1339–1347. doi:10.1016/0092-8674(93)90360-3
 164. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, Glenner GG (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. *Cell* 35:349–358. doi:10.1016/0092-8674(83)90168-X
 165. DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR, Prusiner SB (1985) Identification of prion amyloid filaments in scrapie-infected brain. *Cell* 41:221–235. doi:10.1016/0092-8674(85)90076-5
 166. Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH (2008) Amyloid fibrils of the HET-s(218–289) prion form a beta solenoid with a triangular hydrophobic core. *Science* 319:1523–1526. doi:10.1126/science.1151839
 167. Hou X, Aguilar MI, Small DH (2007) Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. *FEBS J* 274:1637–1650. doi:10.1111/j.1742-4658.2007.05712.x
 168. Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. *Proc Natl Acad Sci USA* 75:4499–4503. doi:10.1073/pnas.75.9.4499
 169. Sousa MM, Cardoso I, Fernandez R, Guimäraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. *Am J Pathol* 159:1993–2000
 170. Monaco HL (2002) Three-dimensional structure of the transthyretin-retinol-binding protein complex. *Clin Chem Lab Med* 40:1229–1236. doi:10.1515/CCLM.2002.213
 171. Redondo C, Damas AM, Saraiva MJ (2000) Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. *Biochem J* 348:167–172. doi:10.1042/0264-6021:3480167
 172. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. *N Engl J Med* 336:466–473. doi:10.1056/NEJM199702133360703
 173. Buxbaum JN, Tagoe CE (2000) The genetics of the amyloidosis. *Annu Rev Med* 51:543–569. doi:10.1146/annurev.med.51.1.543
 174. Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA (1997) Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. *Adv Protein Chem* 50:161–181. doi:10.1016/S0065-3233(08)60321-6
 175. Kelly JW (1998) The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. *Curr Opin Struct Biol* 8:101–106. doi:10.1016/S0959-440X(98)80016-X
 176. Reixach N, Deechongkit S, Jian X, Kelly JW, Buxbaum JN (2004) Tissue damage in the amyloidosis: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. *Proc Natl Acad Sci USA* 101:2817–2822. doi:10.1073/pnas.0400062101
 177. Kelly JW (1997) Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. *Structure* 5:595–600. doi:10.1016/S0969-2126(97)00215-3
 178. Nichols WC, Dwulet FE, Liepnieks J, Benson MD (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. *Biochem Biophys Res Commun* 156:762–768. doi:10.1016/S0006-291X(88)80909-4
 179. Gorevic PD, Munoz PC, Gorgone G, Purcell JJ Jr, Rodrigues M, Ghiso J, Levy E, Haltia M, Frangione B (1991) Amyloidosis due to a mutation of the gelsolin gene in an American family with lattice corneal dystrophy type II. *N Engl J Med* 325:1780–1785
 180. Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B (1990) Mutation in gelsolin gene in Finnish hereditary amyloidosis. *J Exp Med* 172:1865–1867. doi:10.1084/jem.172.6.1865
 181. de la Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury CP, Kere J (1992) Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. *Nat Genet* 2:157–160. doi:10.1038/ng1092-157
 182. Wisniewski T, Golabek A, Kida E, Wisniewski K, Frangione B (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. *Am J Pathol* 147:238–244
 183. Maury CP, Kere J, Tolvanen R, de la Chapelle A (1990) Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. *FEBS Lett* 276:75–77. doi:10.1016/0014-5793(90)80510-P
 184. Kiuru S (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. *Amyloid* 5:55–66
 185. Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, Balch WE (2001) Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca²⁺ stabilization. *EMBO J* 20:6277–6287. doi:10.1093/emboj/20.22.6277
 186. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, Kelly JW, Balch WE (2005) Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. *EMBO J* 24:4124–4132. doi:10.1038/sj.emboj.7600872
 187. Bhattacharya S, Latha JN, Kumresan R, Shashi S (2007) Cloning and expression of human islet amyloid polypeptide in cultured cells. *Biochem Biophys Res Commun* 365:8–15
 188. Westermark P (1994) Amyloid and polypeptide hormones: what is their inter-relationship? *Amyloid* 1:47–60. doi:10.3109/13506129409148624

189. Koopmans SJ, Radder JK, Krans HM, Barge RM (1992) Biological action of pancreatic amylin: relationship with glucose metabolism, diabetes, obesity and calcium metabolism. *Neth J Med* 41:82–90
190. Cooper GJ, Day AJ, Willis AC, Roberts AN, Reid KB, Leighton B (1989) Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. *Biochim Biophys Acta* 1014:247–258. doi:10.1016/0167-4889(89)90220-6
191. Edwards BJ, Morley JE (1992) Amylin. *Life Sci* 51:1899–1912. doi:10.1016/0024-3205(92)90106-Y
192. Nilsson MR, Raleigh DP (1999) Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. *J Mol Biol* 294:1375–1385. doi:10.1006/jmbi.1999.3286
193. Anguiano M, Nowak RJ, Lansbury PT (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. *Biochemistry* 41:11338–11343. doi:10.1021/bi020314u
194. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuro-peptide-like protein also present in normal islet cells. *Proc Natl Acad Sci USA* 84:3881–3885. doi:10.1073/pnas.84.11.3881
195. Rosano C, Zuccotti S, Bolognesi M (2005) The three-dimensional structure of β 2 microglobulin: results from X ray crystallography. *Biochim Biophys Acta* 1753:85–91
196. Floege J, Ehlerding G (1996) Beta-2-microglobulin associated amyloidosis. *Nephron* 72:9–26. doi:10.1159/000188801
197. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen AS, Schmid K (1985) A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. *Biochem Biophys Res Commun* 129:701–706. doi:10.1016/0006-291X(85)91948-5
198. Gouin-Charnet A, Mourad G, Argilés A (1997) Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. *Biochem Biophys Res Commun* 231:48–51. doi:10.1006/bbrc.1996.6019
199. Trinh CH, Smith DP, Kalverda AP, Philips SE, Radford S (1991) Crystal structure of monomeric human β -2-microglobulin reveals clues to its amyloidogenic properties. *Proc Natl Acad Sci USA* 99:9771–9776. doi:10.1073/pnas.152337399
200. McParland VJ, Kad NM, Kalverda AP, Brown A, Kirwin-Jones P, Hunter MG, Sunde M, Radford SE (2000) Partially unfolded states of beta(2)-microglobulin amyloid formation in vitro. *Biochemistry* 39:8735–8746. doi:10.1021/bi000276j
201. Ohhashi Y, Hagihara Y, Kozhukh G, Hoshino M, Hasegawa K, Yamaguchi I, Naiki H, Goto Y (2002) The intrachain disulfide bond of beta(2)-microglobulin is not essential for the immunoglobulin fold at neutral pH, but is essential for amyloid fibril formation at acidic pH. *J Biochem* 131:45–52
202. Gribbin JR (2004) Deep simplicity: bringing order to chaos and complexity. Random House Inc., New York, pp 1–304
203. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, Hultgren SJ (2002) Role of *Escherichia coli* curli operons in directing amyloid fiber formation. *Science* 295:851–855. doi:10.1126/science.1067484
204. Claessen D, Rink R, de Jong W, Siebring J, de Vreugd P, Bowersma FG, Dijkhuizen L, Wosten HA (2003) A novel class of secreted hydrophobic proteins is involved in aerial hyphae formation in *Streptomyces coelicolor* by forming amyloid-like fibrils. *Genes Dev* 17:1714–1726. doi:10.1101/gad.264303
205. Mackay JP, Matthews JM, Winefield RD, Mackay LG, Haverkamp RG, Templeton MD (2001) The hydrophobin EAS is largely unstructured in solution and functions by forming amyloid-like structures. *Structure* 9:83–91. doi:10.1016/S0969-2126(00)00559-1
206. Coustou V, Deleu C, Saupe S, Begueret J (1997) The protein product of the het-s heterokaryon incompatibility gene of the fungus *Podospora anserina* behaves as a prion analog. *Proc Natl Acad Sci USA* 94:9773–9778. doi:10.1073/pnas.94.18.9773
207. King CY, Tittmann P, Gross H, Gebert R, Aepli M, Wüthrich K (1997) Prion-inducing domain 2-114 of yeast Sup35 protein transforms in vitro into amyloid-like filaments. *Proc Natl Acad Sci USA* 94:6618–6622. doi:10.1073/pnas.94.13.6618
208. Iconomidou VA, Vriend G, Hamodrakas SJ (2000) Amyloids protect the silkworm oocyte and embryo. *FEBS Lett* 479:141–145. doi:10.1016/S0014-5793(00)01888-3
209. Iconomidou VA, Chryssikos GD, Gionis V, Galanis AS, Coropatis P, Hoenger A, Hamodrakas SJ (2006) Amyloid fibril formation propensity is inherent into the hexapeptide tandemly repeating sequence of the central domain of silkworm chorion proteins of the A-family. *J Struct Biol* 156:480–488. doi:10.1016/j.jsb.2006.08.011
210. Kobayashi T, Urabe K, Orlow SJ, Higashi K, Imokawa G, Kwon BS, Potterf B, Hearing VJ (1994) The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function. *J Biol Chem* 269:29198–29205
211. Kelly JW, Balch WE (2003) Amyloid as a natural product. *J Cell Biol* 161:461–462. doi:10.1083/jcb.200304074
212. DeLano WL (2002) The PyMOL molecular graphics system. DeLano Scientific, Palo Alto. <http://www.pymol.org>